Leadership
Our Team
Experienced pharmaceutical industry veterans with deep expertise in device development, formulation science, and regulatory affairs.
Leadership experience spanning original and generic respiratory products, DPI and pMDI development, formulation, analytical strategy, device engineering, industrialisation and global commercialisation.
John Denny
Founder & Chief Executive Officer
Thirty years leading pharmaceutical device development at GSK, Mylan, and AstraZeneca. Former VP Global Pharmaceutical Device Development at Mylan. West Point graduate (BS Mechanical Engineering) who founded Knightpoint in 2017 to build a new kind of specialty pharmaceutical company - one that controls both device and formulation.
Eric Richardson
Device Engineering Manager
30 years of mechanical engineering expertise with 23 years focused exclusively on respiratory drug delivery devices. Former Director of Product Development at Respirics, product engineer at Bespak Ltd and 3M Riker Laboratories. Named inventor on multiple DPI patents. Founded Syphase LLC consulting firm and served as COO at Concentrx Pharmaceuticals.
Andy Burgess
Chief Scientific Officer
21+ years in Respiratory Product Development within R&D at GSK, leading analytical and formulation work for CMC sections of NDAs across multiple DPI and pMDI product generations. Additional 15 years expertise in strategic sourcing and supplier development for excipients, packaging, and devices. Deep expertise in combination product formulation.
Russell F. Spencer
Chief Commercial Officer
30+ years of global pharmaceutical experience spanning technical, program management, and business development across originator and generic markets. Founder of Virtual Pharma Alliance, providing strategic outsourcing and alliance management for pharmaceutical development. Expertise in deal structures, portfolio development, and supply chain optimization.
Why We Built Knightpoint Group
We saw an opportunity to do something different in respiratory pharmaceuticals. By controlling both device and formulation development in-house, we can deliver better products, faster - and at lower cost to patients.
Our team combines decades of experience from leading pharmaceutical companies with the agility of a focused specialty pharma organization. We're building Knightpoint Group to be a different kind of pharmaceutical company - one that owns the entire system from device to drug to delivery.
Strategic and Corporate Development Enquiries
For confidential discussions about acquiring, developing or selectively licensing the Mirai™ platform, connect with our leadership.
Discuss a Strategic Transaction